Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients

Inclusion Criteria: * Age\>18 years * Written informed consent * Glomerular Filtration Rate (GFR)≥ 30 ml/min/1.73m2 \[CKD stage G1-G3\] * Percutaneous coronary intervention in patients with NSTEMI, UA, STCD and asymptomatic patients Exclusion Criteria: * Active malignancy * Class I or equivalent indication for treatment with a SGLT2 inhibitor * Pregnancy or willing of pregnancy during the follow up period * Active urogenital infection * Diabetes mellitus type 1 * History of diabetic ketoacidosis * Cardiogenic shock * eGFR \< 29 ml/min/1.73m2